cancer Archives | Be Korea-savvy
Chosun University Hospital Turns to AI for Cancer Treatment

Chosun University Hospital Turns to AI for Cancer Treatment

GWANGJU, Nov. 5 (Korea Bizwire) — Chosun University Hospital in Gwangju announced on Sunday that it is using Watson for Oncology, a medical AI supercomputer designed by IBM Inc., for cancer treatment. Once the information about a patient along with the preliminary diagnosis is entered, Watson delivers the optimum method of treatment by analyzing its [...]

NANOBIOTIX: Positive Phase II/III Results for NBTXR3 in Soft Tissue Sarcoma Presented at ESMO

NANOBIOTIX: Positive Phase II/III Results for NBTXR3 in Soft Tissue Sarcoma Presented at ESMO

Paris, France, and Cambridge, Massachusetts (USA), Oct. 19 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, presented NBTXR3 positive Phase II/III Act.in.sarc results in patients with locally advanced Soft Tissue Sarcoma at the European Society for Medical Oncology (ESMO) 2018 Congress [...]

Cancer Mortality Rates in South Korea Second Lowest Amongst OECD Nations

Cancer Mortality Rates in South Korea Second Lowest Amongst OECD Nations

SEOUL, Sept. 27 (Korea Bizwire) — The number of Koreans who succumbed to cancer last year was found to be a record high, but compared to other advanced nations, the mortality rate from cancer remained low. Meanwhile, the mortality rate of South Koreans, in general, was low among other leading nations, but deaths from pneumonia, [...]

Nanobiotix to Present Positive Results from its Phase II/III Clinical Trial of NBTXR3 in Patients with Soft Tissue Sarcoma (STS) and Other Ongoing Phase I/II Trials at Upcoming ESMO and ASTRO Annual Conferences

Nanobiotix to Present Positive Results from its Phase II/III Clinical Trial of NBTXR3 in Patients with Soft Tissue Sarcoma (STS) and Other Ongoing Phase I/II Trials at Upcoming ESMO and ASTRO Annual Conferences

PARIS, France and CAMBRIDGE, Massachusetts, Sept. 26 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that detailed results of its phase II/III clinical trial of NBTXR3 in patients with soft tissue sarcoma (STS) will be presented by Dr. Sylvie Bonvalot, [...]

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101

NEW YORK, Sept. 25 (Korea Bizwire) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday [...]

IASLC Invites Lung Cancer Professionals to Take Global Survey on Molecular Testing

IASLC Invites Lung Cancer Professionals to Take Global Survey on Molecular Testing

DENVER, Jul. 11, 2018 (Korea Bizwire) — The International Association for the Study of Lung Cancer (IASLC) encourages all those involved in molecular testing of lung cancer patients to participate in a global survey designed to assess the implementation of best practices and ultimately develop worldwide guidelines for molecular testing. To take the IASLC Global [...]

AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting

AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting

CAMBRIDGE, United Kingdom, Apr. 16 (Korea Bizwire) — AstraZeneca and MedImmune, its global biologics research and development arm, today presented efficacy and safety data from two Phase I trials evaluating Imfinzi (durvalumab) in combination with tremelimumab in 2nd-line immunotherapy-naïve patients with either non-squamous advanced non-small cell lung cancer (NSCLC) (Study 006) or metastatic urothelial carcinoma [...]

Samsung Bioepis’ Ontruzant Hits Britain

Samsung Bioepis’ Ontruzant Hits Britain

SEOUL, Mar. 9 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. said Friday its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator. Global health care company MSD has begun distributing the biosimilar that references Switzerland-based Roche Holding’s Herceptin, also known as Trastuzumab, in the country, Samsung [...]